National Healthcare's MACD Death Cross Signals Bearish Trend with Bearish Marubozu Candle.

National Healthcare's 15-minute chart has recently exhibited a MACD Death Cross and a Bearish Marubozu on September 19, 2025 at 10:15. This technical indicator suggests that the stock price has the potential to continue its downward trajectory, with sellers dominating the market and bearish momentum expected to persist.

Advanced Biomed Inc. (ADVB), a leading player in the biomedical technology sector, has recently announced the launch of its latest innovation, the A+PerfusC™ integrated perfusion 3D cell culture platform. This groundbreaking technology is designed to cater to precision medicine and drug discovery applications, positioning ADVB at the forefront of biomedical advancements.

The A+PerfusC™ platform features a compact, all-in-one design that supports up to 12 days of continuous, hands-free culture with the capacity for 4,800 tumor spheroids per plate. Key features include 8 independent channels per plate, compatibility with 96/384 well plates for high-throughput screening, and the ability to mount a microscope for real-time observation. The platform has successfully completed internal testing and validation, with mass production development currently underway.

The launch of A+PerfusC™ targets the growing global 3D cell culture market, which is valued at $2.32 billion in 2025 and is projected to reach $4.71 billion by 2030, with a compound annual growth rate (CAGR) of 15.6% Advanced Biomed Inc. Stock Price, News & Analysis^[1]. This platform is expected to contribute significantly to ADVB’s revenue and market share in the coming years.

In addition to this significant innovation, ADVB has also recently completed its Initial Public Offering (IPO), raising $6.56 million in gross proceeds through the sale of 1,640,000 common stock shares at $4.00 per share. The IPO, which began trading on the Nasdaq Capital Market under ticker 'ADVB' on March 6, 2025, will fund various initiatives including IVD clinical research, chip design and development, facility upgrades, market expansion, marketing and sales initiatives, and general working capital Replace Welltower With National Health Investors^[2].

The company’s focus on microfluidic technology for cancer detection and treatment, along with its suite of innovative devices such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, underscores its commitment to advancing healthcare through technology. ADVB’s strategic partnerships and regulatory approvals have further solidified its position in the biomedical sector, making it a company to watch for investors and industry professionals alike.

As the stock market continues to evolve, investors should keep an eye on ADVB’s financial performance and technological advancements. The recent launch of A+PerfusC™ and the successful completion of the IPO indicate a strong future trajectory for the company.

References

Advanced Biomed Inc. Stock Price, News & Analysis^[1] https://www.stocktitan.net/news/ADVB/
Replace Welltower With National Health Investors^[2] https://seekingalpha.com/article/4823844-replace-welltower-with-national-health-investors?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=b4f7106fbaa6456eaa9eb8cab85e298a